Coen Steven P. 4
4 · Ginkgo Bioworks Holdings, Inc. · Filed Apr 14, 2026
Research Summary
AI-generated summary of this filing
Ginkgo (DNA) CFO Steven Coen Sells 33,171 Shares to Cover Taxes
What Happened
Steven Coen, Chief Financial Officer of Ginkgo Bioworks (DNA), had performance-based restricted stock units (PSUs) convert into 73,921 shares of Class A common stock on April 10, 2026 (two PSU awards: 28,368 and 45,553 shares). On April 13, 2026 he sold 33,171 of those shares in an open-market transaction at $6.41 per share for total proceeds of $212,759. The sale was a sell-to-cover to satisfy tax withholding tied to the PSU vesting.
Key Details
- Transaction dates: PSUs converted to shares on 2026-04-10; open-market sale on 2026-04-13.
- Sale price and value: 33,171 shares sold at $6.41 each, proceeds $212,759.
- Shares involved: 73,921 total shares distributed on vesting (28,368 and 45,553 from two PSU grants); 33,171 sold to cover taxes.
- Shares remaining (after sell-to-cover): approximately 40,750 shares retained (73,921 vested − 33,171 sold), per the filing.
- Footnotes: F1–F4 explain PSUs convert 1:1 into Class A shares and detail the original PSU grants and performance payout rates (62% and 67% of targets). F2 confirms the sale was to satisfy tax withholding and not a discretionary trade.
- Timeliness: Form 4 was filed April 14, 2026 for a report period of April 10, 2026 — the filing appears timely under Form 4 rules.
Context
- PSUs are performance-based awards that convert to shares when performance periods end and targets are certified; here the Compensation Committee certified partial payouts for two 2025 grants.
- The sequence (PSU conversion followed by a sell-to-cover) is common when companies or executives sell a portion of vested shares to meet tax obligations; per the filing, this sale was for tax withholding and not an independent, discretionary sale decision.
- This filing does not indicate other discretionary buying or selling by the CFO beyond the sell-to-cover.
Insider Transaction Report
Form 4
Coen Steven P.
See remarks
Transactions
- Exercise/Conversion
Class A Common Stock
[F1]2026-04-10+28,368→ 37,467 total - Exercise/Conversion
Class A Common Stock
[F1]2026-04-10+45,553→ 83,020 total - Sale
Class A Common Stock
[F2]2026-04-13$6.41/sh−33,171$212,759→ 49,849 total - Exercise/Conversion
Performance-Based Restricted Stock Unit
[F1][F3]2026-04-10−28,368→ 0 total→ Class A Common Stock (28,368 underlying) - Exercise/Conversion
Performance-Based Restricted Stock Unit
[F1][F4]2026-04-10−45,553→ 0 total→ Class A Common Stock (45,553 underlying)
Footnotes (4)
- [F1]Each performance-based restricted stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
- [F2]Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction.
- [F3]On March 6, 2025, the Reporting Person was granted 45,755 based on a finance team cash flow reduction target over a one-year period beginning on January 1, 2025 and ending on December 31, 2025. The total number of vested PSUs distributed by Issuer on April 10, 2026 in the form of Class A Common Stock reflects actual performance equal to 62% of the finance team target, as certified by the Compensation Committee of the Board of Directors.
- [F4]On May 21, 2025, in connection with the Reporting Person's elevation to Chief Financial Officer, the Reporting Person was granted 67,991 PSUs based on a company-wide cash flow reduction target over a one-year period beginning on January 1, 2025 and ending on December 31, 2025. The total number of vested PSUs distributed by Issuer on April 10, 2026 in the form of Class A Common Stock reflects actual performance equal to 67% of the company-wide target, as certified by the Compensation Committee of the Board of Directors.
Signature
/s/ Karen Tepichin, Attorney-in-Fact|2026-04-14